TRVI
Trevi TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
TRVI Profile
Trevi Therapeutics, Inc.
A clinical-stage biopharmaceutical company that develops treatments for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis
Pharmaceutical
03/17/2011
05/07/2019
NASDAQ Stock Exchange
34
12-31
Common stock
195 Church Street, 16th Floor, New Haven, Connecticut 06510
--
Trevi Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 17, 2011. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio, an oral sustained-release nalbuphine formulation for the treatment of chronic cough associated with idiopathic pulmonary fibrosis, other interstitial lung diseases and refractory chronic cough. It retains the global commercial rights to the research therapy.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
